Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue

Dichotomous function of IL-33 in health and disease: From biology to clinical implications

(2018) Harald Braun et al.   BIOCHEMICAL PHARMACOLOGY

Conflicting vascular and metabolic impact of the IL-33/sST2 axis

(2018) Raffaele Altara et al.   CARDIOVASCULAR RESEARCH

Epigenomes in Cardiovascular Disease

(2018) Manuel Rosa-Garrido et al.   CIRCULATION RESEARCH

Predictive value of low interleukin-33 in critically ill patients

(2018) Konstantin A. Krychtiuk et al.   CYTOKINE

Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease

(2018) Tetsuro Tsujimoto et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Brief Report

(2018) Christopher deFilippi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2

(2018) Stefan Stojkovic et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART‐2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study

(2018) Takuya Oikawa et al.   Journal of the American Heart Association

IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets

(2017) Stefan Stojkovic et al.   THROMBOSIS AND HAEMOSTASIS

Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure

(2017) Ståle H. Nymo et al.   JACC-Heart Failure

Diagnostic performance and reference values of novel biomarkers of paediatric heart failure

(2016) Jakob A Hauser et al.   HEART

Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1/LXRα signalling pathway in oxLDL-loaded macrophages

(2016) Xiaoyang Xu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells

(2016) Eliana Montanari et al.   THROMBOSIS AND HAEMOSTASIS

Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation

(2016) Stefan Stojkovic et al.   Scientific Reports

Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells

(2015) Heidrun Karlic et al.   Cancer Genetics

Interleukin-33 induces urokinase in human endothelial cells―possible impact on angiogenesis

(2014) S. Stojkovic et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome

(2014) Svitlana Demyanets et al.   PLoS One

Regulation of mevalonate metabolism in cancer and immune cells

(2013) Martin Thurnher et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

MicroRNA-22 Downregulation by Atorvastatin in a Mouse Model of Cardiac Hypertrophy: a new Mechanism for Antihypertrophic Intervention

(2013) Yingfeng Tu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Atorvastatin, Etidronate, or Both in Patients at High Risk for Atherosclerotic Aortic Plaques

(2013) Tetsuya Kawahara et al.   CIRCULATION

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature

(2013) Svitlana Demyanets et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells

(2012) Arnaud Hot et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice

(2012) Jian Yang et al.   CARDIOVASCULAR RESEARCH

Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus

(2012) Tao Rui et al.   CARDIOVASCULAR RESEARCH

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo

(2012) Jian Yang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue

(2012) M Zeyda et al.   INTERNATIONAL JOURNAL OF OBESITY

Interleukin 33 as a Mechanically Responsive Cytokine Secreted by Living Cells

(2012) Rahul Kakkar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interleukin-33 Induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques

(2011) Svitlana Demyanets et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Statins and myocardial remodelling: cell and molecular pathways

(2011) Karen E. Porter et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras–ERK pathways

(2010) Narimasa Takayama et al.   HYPERTENSION RESEARCH

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy

(2010) Yang Ye et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats

(2009) Liang Li et al.   BIOCHEMICAL PHARMACOLOGY

Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling

(2009) Kenjiro Seki et al.   Circulation-Heart Failure

Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: Involvement of the RhoA/Rho kinase pathway

(2009) Yang Ye et al.   FEBS LETTERS

Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases

(2009) Alexander U. Lüthi et al.   IMMUNITY

Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1α, tumour necrosis factor-α and transforming growth factor-β

(2009) Rudolf Jarai et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET